77 related articles for article (PubMed ID: 33258324)
1. A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up.
Song SH; Kim JK; Lee H; Lee S; Hong SK; Byun SS
Investig Clin Urol; 2021 Jan; 62(1):32-38. PubMed ID: 33258324
[TBL] [Abstract][Full Text] [Related]
2. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
Leclercq L; Bastide C; Lechevallier E; Walz J; Charvet AL; Gondran-Tellier B; Campagna J; Savoie PH; Long-Depaquit T; Daniel L; Rossi D; Pignot G; Baboudjian M
Fr J Urol; 2024 Mar; 34(2):102571. PubMed ID: 38717459
[TBL] [Abstract][Full Text] [Related]
4. Low-risk Prostate Cancer: Identification, Management, and Outcomes.
Moschini M; Carroll PR; Eggener SE; Epstein JI; Graefen M; Montironi R; Parker C
Eur Urol; 2017 Aug; 72(2):238-249. PubMed ID: 28318726
[TBL] [Abstract][Full Text] [Related]
5. Impact of a negative confirmatory biopsy on risk of disease progression among men on active surveillance for prostate cancer.
Salari K; Kowitz J; Twum-Ampofo J; Gusev A; O'Shea A; Anderson MA; Harisinghani M; Kuppermann D; Dahl DM; Efstathiou JA; Lee RJ; Blute ML; Zietman AL; Feldman AS
Urol Oncol; 2023 Sep; 41(9):387.e9-387.e16. PubMed ID: 37208229
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.
Simpkin AJ; Tilling K; Martin RM; Lane JA; Hamdy FC; Holmberg L; Neal DE; Metcalfe C; Donovan JL
Eur Urol; 2015 Jun; 67(6):993-1005. PubMed ID: 25616709
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.
Lange JM; Laviana AA; Penson DF; Lin DW; Bill-Axelson A; Carlsson SV; Newcomb LF; Trock BJ; Carter HB; Carroll PR; Cooperberg MR; Cowan JE; Klotz LH; Etzioni RB
Cancer; 2020 Feb; 126(3):583-592. PubMed ID: 31639200
[TBL] [Abstract][Full Text] [Related]
8. Can systemic immune-inflammation index and hematologic parameters aid in decision-making for active surveillance or curative treatment in low-risk prostate cancer?
Baylan B; Ulusoy K; Ekenci B; Kartal IG
Asian J Surg; 2024 Mar; 47(3):1360-1365. PubMed ID: 38065745
[TBL] [Abstract][Full Text] [Related]
9. Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study.
Drost FH; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Remmers S; van der Poel HG; Bangma CH; Roobol MJ;
Transl Androl Urol; 2018 Feb; 7(1):98-105. PubMed ID: 29594024
[TBL] [Abstract][Full Text] [Related]
10. The Brazilian national prospective active surveillance (AS) cohort of patients with low-risk prostate cancer in the public health system: vigiaSUS study protocol.
Basso J; de Lima JB; Bessel M; Tobar Leitão SA; Machado Baptista T; Roithmann S; Franco Carvalhal E; da Silva Schmitt C; Morzoletto Pedrollo I; Schuch A; Atalibio Hartmann A; Neubarth Estivallet CL; Behrend Silva Ribeiro G; Zordan RA; Isaacsson Velho P
BMC Urol; 2023 Dec; 23(1):208. PubMed ID: 38082337
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance.
Marshall DT; Savage SJ; Garrett-Mayer E; Keane TE; Hollis BW; Horst RL; Ambrose LH; Kindy MS; Gattoni-Celli S
J Clin Endocrinol Metab; 2012 Jul; 97(7):2315-24. PubMed ID: 22508710
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience.
Bandelier Q; Bastide C; Charvet AL; Leclercq L; Gondran-Tellier B; Campagna J; Long-Depaquit T; Daniel L; Rossi D; Lechevallier E; Baboudjian M
Fr J Urol; 2024 Jan; 34(1):102537. PubMed ID: 37783635
[TBL] [Abstract][Full Text] [Related]
13. Systemic Inflammatory Index: A Novel Biomarker for Predicting the Progression in Active Surveillance in Patients with Prostate Cancer.
Ozcan L; Omur M; Polat EC; Baran C; Boylu A; Otunctemur A
J Coll Physicians Surg Pak; 2023 Nov; 33(11):1278-1282. PubMed ID: 37926881
[TBL] [Abstract][Full Text] [Related]
14. Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance. Letter.
Peng CK; Wang SC; Chen SL; Sung WW
J Urol; 2023 Oct; 210(4):580-581. PubMed ID: 37584320
[No Abstract] [Full Text] [Related]
15. Clinical management and outcomes of HIV-positive patients newly diagnosed with prostate cancer: a single institution experience.
Markowski MC; Pirsl F; Keruly JC; Chander G; Moore RD; Lau B; Joshu CE
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):144-146. PubMed ID: 36057651
[TBL] [Abstract][Full Text] [Related]
16. CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Sheikhbahaei S; Reyes DK; Rowe SP; Pienta KJ
Prostate; 2021 Feb; 81(2):127-134. PubMed ID: 33259087
[TBL] [Abstract][Full Text] [Related]
17. Surgical Delay and Pathological Outcomes for Clinically Localized High-Risk Prostate Cancer.
Xia L; Talwar R; Chelluri RR; Guzzo TJ; Lee DJ
JAMA Netw Open; 2020 Dec; 3(12):e2028320. PubMed ID: 33289846
[TBL] [Abstract][Full Text] [Related]
18. Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance.
Salguero J; Gómez-Gómez E; Valero-Rosa J; Carrasco-Valiente J; Mesa J; Martin C; Campos-Hernández JP; Rubio JM; López D; Requena MJ
Korean J Radiol; 2021 Apr; 22(4):559-567. PubMed ID: 33289358
[TBL] [Abstract][Full Text] [Related]
19. Robotic radical prostatectomy: analysis of midterm pathologic and oncologic outcomes: A historical series from a high-volume center.
Asimakopoulos AD; Annino F; Mugnier C; Lopez L; Hoepffner JL; Gaston R; Piechaud T
Surg Endosc; 2021 Dec; 35(12):6731-6745. PubMed ID: 33289056
[TBL] [Abstract][Full Text] [Related]
20. Germline DNA-Repair Genes and HOXB13 Mutations in Korean Men with Metastatic Prostate Cancer: Data from a Large Korean Cohort.
Song SH; Kim HM; Jung YJ; Kook HR; Jeon S; Bhak J; Kim JH; Lee H; Oh JJ; Lee S; Hong SK; Byun SS
World J Mens Health; 2023 Oct; 41(4):960-968. PubMed ID: 37118955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
